Research background · Updated November 1, 2026
Cagrilintide Research: Publications, Study Types and Background
Short answer
Cagrilintide is listed as acylated (lipidated) amylin analogue peptide. As of November 1, 2026, PubMed indexes 105 records matching Cagrilintide, the earliest from 2021; 60 were published in 2021–2025 and 50 are reviews. ClinicalTrials.gov lists 45 registered studies matching the compound.
- PubMed records
- 105
- Earliest record
- 2021
- Published 2021–2025
- 60
- Reviews
- 50
- Animal-only studies
- 6
- Registered studies
- 45
Publications per year, 2006–2025
63 records in 2016–2025 against 0 in 2006–2015; the busiest year was 2025, with 30.
See the numbers
| Year | PubMed records |
|---|---|
| 2006 | 0 |
| 2007 | 0 |
| 2008 | 0 |
| 2009 | 0 |
| 2010 | 0 |
| 2011 | 0 |
| 2012 | 0 |
| 2013 | 0 |
| 2014 | 0 |
| 2015 | 0 |
| 2016 | 0 |
| 2017 | 0 |
| 2018 | 0 |
| 2019 | 0 |
| 2020 | 0 |
| 2021 | 8 |
| 2022 | 6 |
| 2023 | 5 |
| 2024 | 14 |
| 2025 | 30 |
Study types
| All PubMed records | 105 |
|---|---|
| Reviews | 5048% |
| Animal studies (no human subjects indexed) | 66% |
| Indexed as clinical trials | 1514% |
| Registered on ClinicalTrials.gov | 45 |
Categories overlap and follow PubMed’s own indexing; recent records may not be indexed yet.
Primary research directions
What 7 of the most-cited and most recent Cagrilintide papers report, in their own authors’ terms. Each line links the paper it came from.
This systematic review and meta-analysis of five trials reports that the cagrilintide-semaglutide combination (CagriSema) produced greater weight loss than semaglutide alone, with no incremental glycaemic benefit detected and more frequent injection-site reactions; long-term outcomes remain undetermined.
ReviewRasool ZK 2026Frontiers in endocrinologyPMID 42890523
This network meta-analysis of trials in adults with type 2 diabetes reports that, among the GLP-1 receptor agonist treatments compared, CagriSema (semaglutide with cagrilintide) resulted in the highest weight loss versus placebo, and raises concerns about gastrointestinal adverse events.
ReviewYao H 2024BMJ (Clinical research ed.)PMID 38286487
In a phase 3a randomized trial in adults with overweight or obesity without diabetes, cagrilintide-semaglutide was associated with significantly greater body-weight reduction than placebo; gastrointestinal adverse events were more common and mainly transient and mild-to-moderate.
HumansGarvey WT 2025The New England journal of medicinePMID 40544433
In a phase 3a randomized trial in adults with overweight or obesity and type 2 diabetes, cagrilintide-semaglutide was associated with significantly lower body weight than placebo and more patients reaching low glycated hemoglobin; gastrointestinal adverse events were more frequent, mostly transient.
HumansDavies MJ 2025The New England journal of medicinePMID 40544432
In a phase 2 randomized trial in adults with type 2 diabetes, CagriSema was associated with a greater HbA1c reduction than cagrilintide alone but not than semaglutide alone, and greater weight loss than either; mild or moderate gastrointestinal events were most common.
HumansFrias JP 2023Lancet (London, England)PMID 37364590
In a phase 2 trial in adults with overweight or obesity, cagrilintide alone was associated with greater weight reductions than placebo; gastrointestinal adverse events, mainly nausea, were more frequent than with placebo.
HumansLau DCW 2021Lancet (London, England)PMID 34798060
In a phase 1b randomized trial in otherwise healthy adults with overweight or obesity, cagrilintide combined with semaglutide was reported as well tolerated, with mostly mild to moderate adverse events, and greater body-weight reductions than placebo plus semaglutide.
HumansEnebo LB 2021Lancet (London, England)PMID 33894838
Most-studied topics
The Medical Subject Headings (MeSH) PubMed indexers most often marked as a main topic, across 105 of the 105 records. They describe what the literature is about, not what Cagrilintide does.
- Obesity33 papers
- Islet Amyloid Polypeptide26 papers
- Diabetes Mellitus, Type 222 papers
- Anti-Obesity Agents21 papers
- Hypoglycemic Agents13 papers
- Glucagon-Like Peptides12 papers
- Weight Loss11 papers
- Overweight10 papers
Key papers
Earliest indexed record
Enebo LB (2021). Lancet (London, England).
PMID 33894838Most-cited paper · 503 citations
Yao H (2024). BMJ (Clinical research ed.).
PMID 38286487Most-cited #2 · 288 citations
Frias JP (2023). Lancet (London, England).
PMID 37364590Most-cited #3 · 265 citations
Enebo LB (2021). Lancet (London, England).
PMID 33894838
Citation counts from NIH iCite, among the 105 records sampled. Titles are left out; open each record on PubMed to read it.
Identity
| Description | Acylated (lipidated) amylin analogue peptide |
|---|---|
| Supplied form | Lyophilized powder |
| CAS number | 1415456-99-3 |
| Molecular formula | C194H312N54O59S2 |
| Molecular weight | 4409 g/mol |
As published by Vanta Labs, with its sources, on the Cagrilintide page.
How these numbers were counted
- PubMed search, run November 1, 2026:
cagrilintide[tiab]re-run it. Study types add PubMed’s own filters (review, clinical trial, animals not humans). - Topics: MeSH major-topic headings counted across up to 400 of the matching records; headings for study set-up (species, sex, age) are left out.
- Citations: NIH iCite citation counts for the same records.
- ClinicalTrials.gov search:
cagrilintidere-run it. Any phase, any status.
This page reports what has been published and what papers say they found, with each source linked. It gives no dosing or usage information, and nothing here is a reason to use Cagrilintide outside a laboratory.
Wholesale supply
Cagrilintide for research, documented lot by lot.
10mg vials, with a published report printing 99.718% HPLC purity. Every wholesale lot comes with its certificate of analysis, and your quote names the lot. Pricing on inquiry.
Cagrilintide research questions
How much research has been published on Cagrilintide?
PubMed indexes 105 records matching Cagrilintide (searched November 1, 2026), including 50 reviews and 15 records indexed as clinical trials. 60 were published in the five years 2021–2025.
When was Cagrilintide first described in the literature?
The earliest PubMed record matching Cagrilintide is from 2021 (Enebo LB, Lancet (London, England), PMID 33894838).
What topics does the Cagrilintide literature cover?
The subject headings PubMed indexers most often marked as a main topic of Cagrilintide papers are Obesity, Islet Amyloid Polypeptide, Diabetes Mellitus, Type 2, Anti-Obesity Agents. These describe what the literature is about. Findings from individual papers, with their sources, are summarized on this page.
What is the regulatory status of Cagrilintide?
Cagrilintide is not listed as an approved drug in the FDA's Drugs@FDA database (searched 24 September 2026).
Is Cagrilintide sold for human use?
No. Vanta Foundry supplies it for laboratory research use only. Not for human or veterinary use, and not a drug, food, cosmetic or dietary supplement.
Where can I buy Cagrilintide wholesale for research?
From the Vanta Foundry wholesale catalog: add it to your list, choose sizes and the number of vials, and send it on WhatsApp or by email. Every wholesale lot comes with a certificate of analysis.
Research materials supplied by Vanta Foundry are for laboratory research use only. They are not for human or veterinary use and are not drugs, foods, cosmetics or dietary supplements. Websites and payment processing are business services for research-supply brands.
All compounds: research peptide publication statistics.